PurposeThe present study was conducted to compare the pattern of brain [F-18] FDG uptake in suspected non-Alzheimer's pathophysiology (SNAP), AD, and healthy controls using 2-deoxy-2-[F-18]fluoroglucose ([F-18] FDG) positron emission tomography imaging. Cerebrospinal fluid (CSF) biomarkers amyloid-beta 1-42 peptide (A beta 1-42) and tau were used in order to differentiate AD from SNAP.MethodsThe study included 43 newly diagnosed AD patients (female=23; male=20) according to the NINCDS-ADRDA criteria, 15 SNAP patients (female=12; male =3), and a group of 34 healthy subjects that served as the control group (CG), who were found to be normal at neurological evaluation (male=20; female=14). A battery of neuropsychological tests was administrated in AD and SNAP subjects; cerebrospinal fluid assay was conducted in both AD and SNAP as well. Brain PET/CT acquisition was started 305min after [F-18] FDG injection in all subjects. SPM12 [statistical parametric mapping] implemented in MATLAB 2018a was used for the analysis of PET scans in this study.ResultsAs compared to SNAP, AD subjects showed significant hypometabolism in a wide cortical area involving the right frontal, parietal, and temporal lobes. As compared to CG, AD subjects showed a significant reduction in [F-18] FDG uptake in the parietal, limbic, and frontal cortex, while a more limited reduction in [F-18] FDG uptake in the same areas was found when comparing SNAP to CG.Conclusions SNAP subjects show milder impairment of brain [F-18] FDG uptake as compared to AD. The partial overlap of the metabolic pattern between SNAP and AD limits the use of [F-18] FDG PET/CT in effectively discriminating these clinical entities.

Chiaravalloti, A., Barbagallo, G., Martorana, A., Castellano, A.e., Ursini, F., Schillaci, O. (2019). Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 46(9), 1796-1805 [10.1007/s00259-019-04379-4].

Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?

Chiaravalloti A.
;
Martorana A.
;
Schillaci O.
2019-06-01

Abstract

PurposeThe present study was conducted to compare the pattern of brain [F-18] FDG uptake in suspected non-Alzheimer's pathophysiology (SNAP), AD, and healthy controls using 2-deoxy-2-[F-18]fluoroglucose ([F-18] FDG) positron emission tomography imaging. Cerebrospinal fluid (CSF) biomarkers amyloid-beta 1-42 peptide (A beta 1-42) and tau were used in order to differentiate AD from SNAP.MethodsThe study included 43 newly diagnosed AD patients (female=23; male=20) according to the NINCDS-ADRDA criteria, 15 SNAP patients (female=12; male =3), and a group of 34 healthy subjects that served as the control group (CG), who were found to be normal at neurological evaluation (male=20; female=14). A battery of neuropsychological tests was administrated in AD and SNAP subjects; cerebrospinal fluid assay was conducted in both AD and SNAP as well. Brain PET/CT acquisition was started 305min after [F-18] FDG injection in all subjects. SPM12 [statistical parametric mapping] implemented in MATLAB 2018a was used for the analysis of PET scans in this study.ResultsAs compared to SNAP, AD subjects showed significant hypometabolism in a wide cortical area involving the right frontal, parietal, and temporal lobes. As compared to CG, AD subjects showed a significant reduction in [F-18] FDG uptake in the parietal, limbic, and frontal cortex, while a more limited reduction in [F-18] FDG uptake in the same areas was found when comparing SNAP to CG.Conclusions SNAP subjects show milder impairment of brain [F-18] FDG uptake as compared to AD. The partial overlap of the metabolic pattern between SNAP and AD limits the use of [F-18] FDG PET/CT in effectively discriminating these clinical entities.
giu-2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
English
Alzheimer, SNAP; Biomarkers; PET/CT; [18F] FDG; Alzheimer Disease; Amyloid beta-Peptides; Brain; Case-Control Studies; Peptide Fragments; Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18
Chiaravalloti, A., Barbagallo, G., Martorana, A., Castellano, A.e., Ursini, F., Schillaci, O. (2019). Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 46(9), 1796-1805 [10.1007/s00259-019-04379-4].
Chiaravalloti, A; Barbagallo, G; Martorana, A; Castellano, Ae; Ursini, F; Schillaci, O
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/269676
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact